Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by C10H12N2on Mar 09, 2022 12:25am
228 Views
Post# 34498148

RE:RE:Clown Show @ Algernon Pharmaceuticals: Doors Open 24/7/365

RE:RE:Clown Show @ Algernon Pharmaceuticals: Doors Open 24/7/365Yeah, sure. No clowning around when it comes to timelines. Who'd of thought you'd still be waiting for the start of DMT? Yeah, that also means they probably won't meet the start of Phase 2 in Q4 2022. These people are a joke dude. They have got to have the worst timing of any biotech out there. Also, the worst trial designs imaginable - One Arm, One Dose, Open Label BS. No Placebo, No Double Blind, No Power For Statistically Significance. No balls to run clinical trials in North America where the CEO can't pawn all the blame game onto others halfway around the world. The CEO ran his B S clinical trial at Miraculins (dilution on steroids before bankruptcy) on Greece. He's using the same lame a s s playbook with his old Miraculous team now in place at Algernon. Expect massive dilution for the coming capital raise because the CEO can't figure out how to inflate the tires on the bus he clearly drove over the cliff in 2021. As to your belief there's some serious belief management knows what they are doing in the best interest of shareholders, shareholders are holding onto the hope Nasdaq will rescue a failed "Repurposed Drugs" strategy. Most are underwater dude. That's why they are holding. Period. Management will not meet a single deadline this year as currently written. Meaning, the cancer Phase 1's and the Chronic Cough, and the CKD, and whatever other trippe that spews out of the CEOs mouth will fall into the same category of blowing hot air - like the thought of starting a Chronic Cough study this year (2022) once the year long overdue B S data report comes to North America by way of Kangaroo. Moreau had proven time and again you can't believe a single word simultaneously coming out of both sides of his mouth. He's a real circus act unto himself. However. he managed to get Ye Old Circus Band from Miraculins back together again for another 10 Year run with the Devil.
<< Previous
Bullboard Posts
Next >>